RxDoctor Payments Data

Jill Miller, DO

Family Medicine · Saegertown, PANPI 1811148422

Payments from drug & device makers

$4,037in general payments, 2019–2025

Across 201 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$607
  • Acadia Pharmaceuticals Inc$534
  • Novo Nordisk$468
  • Lilly USA, LLC$307
  • AbbVie$245
  • Boehringer Ingelheim$217
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$3,94598%
  • Education$932%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,037 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$106,612
Medicare patients
206
Services billed
1,203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide101$96,691
MounjaroTirzepatide64$73,658
BrixadiBuprenorphine26$40,777
VivitrolNaltrexone Microspheres21$31,457
SublocadeBuprenorphine17$31,152
JardianceEmpagliflozin23$28,100
XareltoRivaroxaban13$20,642
EliquisApixaban14$14,155
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl71$12,417
ZubsolvBuprenorphine Hcl/Naloxone Hcl13$10,707
Varenicline Tartrate16$4,254
Rosuvastatin Calcium89$1,730
Duloxetine Hcl43$1,451
Gabapentin73$1,258
Montelukast Sodium41$1,134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$468$96,691101 claims
Lilly USA, LLCMounjaro$307$73,65864 claims
Braeburn Inc.Brixadi$196$40,77726 claims
Alkermes, Inc.Vivitrol$62$31,45721 claims
Indivior Inc.Sublocade$607$31,15217 claims
Boehringer IngelheimJardiance$217$28,10023 claims
Johnson & JohnsonXarelto$25$20,64213 claims
PfizerEliquis$158$14,15514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Saegertown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →